Zinc alloy implant with calcium-zinc-phosphorus modified layer and preparation method and application thereof

Through phosphate chemical conversion technology, the formation of calcium-zinc-phosphorus modified layer on the surface of zinc alloy implants is solved, and the cytotoxicity and compatibility problems of zinc alloy implants are achieved, achieving its stability and osseous integration in medical care Improvement of capabilities.

CN116115822BActive Publication Date: 2024-12-03SHANDONG UNIV QILU HOSPITAL
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202211572408.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-12-08
Publication Date
2024-12-03
Estimated Expiration
2042-12-08

AI Technical Summary

Technical Problem

Existing zinc alloy implants have cytotoxicity problems, which affects their application in medical care, and poor matching with human bone quality leads to instability.

Method used

The surface modification of the zinc alloy is carried out through phosphate chemical conversion technology to form a calcium-zinc-phosphorus modified layer, reducing the cytotoxicity of the zinc alloy and improving its osteogenic properties. Specific steps include grinding the zinc alloy substrate, surfacturing treatment, soaking in a Ca-Zn-P bath to form a CaZn2(PO4)2·2H2O coating to improve its biocompatibility and bone tissue compatibility.

Benefits of technology

The formed calcium-zinc-phosphorus modified layer has a nanoscale sheet crystal structure, which promotes cell adhesion and osteogenesis, improves the biocompatibility and osseous integration capabilities of zinc alloy implants, reduces the immune response, and enhances the Compatibility with bone tissue.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116115822B_ABST
    Figure CN116115822B_ABST
Patent Text Reader

Abstract

The invention discloses a zinc alloy implant with a calcium-zinc-phosphorus modified layer, a preparation method and an application thereof. The Ca-Zn-P modified layer presents irregular petal-shaped masses formed by stacking of flaky crystals, the flaky crystals are closely arranged, and the irregular petal-shaped masses are loosely distributed on the surface of a zinc alloy matrix. The main phase composition of the calcium-zinc-phosphorus modified layer is CaZn2(PO4)2·2H2O. The microstructural characteristics of the zinc alloy implant with a calcium-zinc-phosphorus modified layer provided by the invention can promote cell adhesion and osteogenesis. The thickness of a single flaky crystal is nanometer-level and the length is micrometer-level. The nanometer-level flaky crystal can induce the formation of osteogenesis and the formation of focal adhesion, and the flaky micro-nano crystal structure can show better structural compatibility with bone tissue.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of zinc alloy implants, and in particular to a zinc alloy implant with a calcium-zinc-phosphorus modified layer, a preparation method and an application thereof. Background Art

[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.

[0003] Implants made of metal are widely used in cardiac surgery, oral surgery, and orthopedics. However, most of the implants currently used are based on titanium alloys. These implants are at risk of prosthesis loosening caused by immune response. During service, toxic metal ions are continuously released into the human body, leading to an inflammatory response and a significant decrease in biocompatibility. In addition, the elastic modulus of most inert metal implants does not match that of human bone, resulting in a stress shielding effect. Ultimately, metal implants become unstable in the body due to reduced stimulation of new bone formation and remodeling. This increases patient pain and medical costs. Therefore, the introduction of bioactive and biodegradable materials that can modulate immune responses is of great benefit to promoting tissue regeneration and bone integration.

[0004] Compared with traditional metal implant materials, degradable metals have received extensive attention from researchers. As a temporary implant material, it can overcome the adverse effects of permanent implant materials. For example, it can avoid secondary surgery, thereby accelerating the tissue regeneration process and reducing additional trauma. However, the clinical application of new generation biomedical materials including iron (Fe), magnesium (Mg) and zinc (Zn) has certain defects. For example, magnesium-based biomaterials are limited in their application in load-bearing parts of bone tissue due to their low mechanical strength and rapid degradation rate. Zinc-based materials with suitable mechanical properties have gradually replaced magnesium alloys as degradable candidate materials for medical applications. Zn also plays an important role in the development process, including immunity, nerves and bone mineralization. Especially in the process of bone formation, Zn plays a pivotal role in promoting the osteogenesis of osteoblasts through proliferation and collagen synthesis processes. However, a large number of studies have shown that Zn implants have serious cytotoxicity. Therefore, further research on zinc-based implants is needed to achieve their perfect performance. Therefore, it is of great significance to explore a material that can reduce the cytotoxicity of zinc alloys and its preparation method. Summary of the invention

[0005] In view of the problems existing in the prior art, the present invention provides a zinc alloy implant with a calcium-zinc-phosphorus modified layer, a preparation method and an application thereof. The surface of the zinc alloy is modified by phosphate chemical conversion technology to obtain a zinc alloy implant with a calcium-zinc-phosphorus modified layer, which reduces the cytotoxicity of the zinc alloy and has good osteogenic properties.

[0006] The technical solution of the present invention is as follows:

[0007] In a first aspect of the present invention, a zinc alloy implant with a calcium-zinc-phosphorus modified layer is provided, comprising a zinc alloy substrate and a calcium-zinc-phosphorus modified layer, wherein the calcium-zinc-phosphorus modified layer presents irregular petal-shaped masses formed by stacking of lamellar crystals, loosely distributed on the surface of the zinc alloy substrate; the main phase composition of the calcium-zinc-phosphorus modified layer is CaZn2(PO4)2·2H2O.

[0008] In a second aspect of the present invention, a method for preparing a zinc alloy implant having a calcium-zinc-phosphorus modified layer is provided, comprising the following steps:

[0009] (1) Grinding the zinc alloy substrate;

[0010] (2) immersing the polished zinc alloy substrate into a colloidal titanium phosphate solution for surface activation treatment;

[0011] (3) immersing the surface-activated zinc alloy substrate in a Ca-Zn-P bath to perform a conversion process; the Ca-Zn-P bath is prepared using H3PO4 with a concentration of 6-8 mL / L, Ca(H2PO4)2·H2O with a concentration of 7.5-8 g / L, Zn(H2PO4)2·2H2O with a concentration of 1.5-2 g / L, NaNO3 with a concentration of 1-3 g / L, and NaNO2 with a concentration of 1-3 g / L;

[0012] (4) The immersed sample is rinsed and dried to obtain a zinc alloy implant having a calcium-zinc-phosphorus modified layer.

[0013] In a third aspect of the present invention, a zinc alloy implant having a calcium-zinc-phosphorus modified layer is provided for use as an implant material in the medical field.

[0014] One or more technical solutions of the present invention have the following beneficial effects:

[0015] (1) The zinc alloy implant with a calcium-zinc-phosphorus modified layer provided by the present invention has a calcium-zinc-phosphorus modified layer on its surface showing irregular petal-shaped masses formed by the accumulation of lamellar crystals. The lamellar crystals are closely arranged, while the irregular petal-shaped masses are loosely distributed on the surface of the matrix. This microstructural feature can promote cell adhesion and osteogenesis; the thickness of a single lamellar crystal is nanometer-level and the length is micrometer-level. The nanoscale lamellar crystals can induce the formation of osteogenesis and focal adhesion, and the lamellar micro-nano crystal structure can show better structural compatibility with bone tissue.

[0016] (2) In the method for preparing a zinc alloy implant having a calcium-zinc-phosphorus modified layer provided by the present invention, since Ca 2+ The Ca-Zn-P modified layer of the prepared zinc alloy implant was successfully doped with Ca. 2+ As an osteogenic element, it can promote osteogenesis.

[0017] (3) Compared with the bare zinc alloy and Zn-P coating, the petal-like morphology formed by the accumulation of the flaky structure of the calcium-zinc-phosphorus modified layer of the present invention can significantly roughen the surface state of the Zn alloy implant. The surface roughness will affect the biological behavior of cells. It acts as a guide for cell contact and forms a mechanical connection on the surface. In addition, the increase in the roughness of the coating will provide a suitable environment for the attachment of cells, which is conducive to achieving a firm bond with bone tissue.

[0018] (4) Compared with the bare zinc alloy and Zn-P coating, the presence of gaps between the platelet crystals in the calcium-zinc-phosphorus modified layer of the present invention leads to a reduction in contact angle and an improvement in wettability. In the chemical conversion process, higher hydrophilicity indicates a more favorable surface coverage. Since cell adhesion depends on the wettability of the surface, a hydrophilic surface is more suitable for cell adhesion.

[0019] (5) The zinc alloy implant with a calcium-zinc-phosphorus modified layer of the present invention promotes bone integration in the bone defect area. The Ca-Zn-P implant can regulate the immune microenvironment through its surface morphology and ion release in the body, thereby resulting in more new bone mass than the bare zinc alloy and Zn-P coating. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.

[0021] Figure 1Surface morphology of a Zn alloy substrate, a zinc alloy implant with a Zn-P coating, and a zinc alloy implant with a Ca-Zn-P modified layer according to an embodiment of the present invention;

[0022] Figure 2 EDS images of a Zn alloy substrate, a zinc alloy implant with a Zn-P coating, and a zinc alloy implant with a Ca-Zn-P modified layer according to an embodiment of the present invention;

[0023] Figure 3 XRD diagrams of a Zn alloy substrate, a zinc alloy implant with a Zn-P coating, and a zinc alloy implant with a Ca-Zn-P modified layer according to an embodiment of the present invention;

[0024] Figure 4 The three-dimensional morphological characteristic diagrams and calculated surface average roughness of a Zn alloy substrate, a zinc alloy implant with a Zn-P coating, and a zinc alloy implant with a Ca-Zn-P modified layer according to an embodiment of the present invention;

[0025] Figure 5 The water drop morphology images and calculated contact angles of the Zn alloy substrate, the zinc alloy implant with the Zn-P coating, and the zinc alloy implant with the Ca-Zn-P modified layer according to the embodiment of the present invention;

[0026] Figure 6 An experimental flow chart for in vivo experimental verification of the immunomodulatory effects of a Zn alloy substrate, a zinc alloy implant with a Zn-P coating, and a zinc alloy implant with a Ca-Zn-P modified layer according to an embodiment of the present invention;

[0027] Figure 7 A Zn alloy substrate, a zinc alloy implant with a Zn-P coating, and a zinc alloy implant with a Ca-Zn-P modified layer according to an embodiment of the present invention were implanted into defects of the femoral shaft, and Micro-CT was performed 8 weeks after surgery to evaluate the bone integration in vivo;

[0028] Figure 8 A Zn alloy substrate, a zinc alloy implant with a Zn-P coating, and a zinc alloy implant with a Ca-Zn-P modified layer according to an embodiment of the present invention were implanted into defects in the femoral shaft, and H&E staining, Ladewig staining, and Calcein / Alizarin Red staining were performed on tissue sections 8 weeks after surgery. DETAILED DESCRIPTION

[0029] It should be noted that the following detailed descriptions are illustrative and are intended to provide further explanation of the present application. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present application belongs.

[0030] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit the exemplary embodiments according to the present application. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should be understood that when the terms "comprising" and / or "including" are used in this specification, it indicates the presence of features, steps, operations, devices, components and / or combinations thereof. If the experimental methods of specific conditions are not indicated in the following specific embodiments, they are usually in accordance with the conventional methods and conditions of biology in the art, and such techniques and conditions are fully explained in the literature.

[0031] In order to solve the problems existing in existing metal alloy implants, in a typical specific embodiment of the present invention, a zinc alloy implant with a calcium-zinc-phosphorus modified layer is provided, comprising a zinc alloy substrate and a calcium-zinc-phosphorus modified layer, wherein the calcium-zinc-phosphorus modified layer presents irregular petal-shaped agglomerates formed by the accumulation of lamellar crystals, which are loosely distributed on the surface of the zinc alloy substrate; the main phase composition of the calcium-zinc-phosphorus modified layer is CaZn2(PO4)2·2H2O.

[0032] Furthermore, the thickness of a single plate-like crystal is less than 10 nm, the length is 10-20 μm, and the edge of the plate-like crystal is in a herringbone shape.

[0033] The present invention adopts a degradable material zinc alloy and performs surface modification on the zinc alloy through phosphate chemical conversion technology (PCC). When constructing the coating, the introduction of functional metal elements can obtain a micro-nano morphology that is conducive to cell adhesion, immunomodulation and bone binding, thereby playing a role in promoting osteogenesis, antibacterial and immunomodulation. In the product, zinc phosphate (Zn-P) and calcium phosphate (Ca-Zn-P) coatings are designed and constructed on the surface of zinc alloy implants through the PCC method. By controlling the composition and reaction parameters of the conversion solution, the different morphologies of the PCC coated Zn implants (Zn-P implants are disc-shaped crystals, and Ca-Zn-P implants are flaky crystals) are adjusted. Due to the introduction of Ca in the coating 2+ and PO4 3- The zinc alloy implant with Ca-Zn-P modified layer prepared by the method of osteogenic elements such as ions can show good osteogenic properties. In addition, Ca-Zn-P has the morphology of micro-nano flake crystals, which is a benefit for macrophages to polarize to M2 type. The material can achieve the effect of promoting osteogenesis.

[0034] In another specific embodiment of the present invention, a method for preparing a zinc alloy implant having a calcium-zinc-phosphorus modified layer is provided, comprising the following steps:

[0035] (1) Grinding the zinc alloy substrate;

[0036] (2) immersing the polished zinc alloy substrate into a colloidal titanium phosphate solution for surface activation treatment;

[0037] (3) immersing the surface-activated zinc alloy substrate in a Ca-Zn-P bath to perform a conversion process; the Ca-Zn-P bath is prepared using H3PO4 with a concentration of 6-8 mL / L, Ca(H2PO4)2·H2O with a concentration of 7.5-8 g / L, Zn(H2PO4)2·2H2O with a concentration of 1.5-2 g / L, NaNO3 with a concentration of 1-3 g / L, and NaNO2 with a concentration of 1-3 g / L;

[0038] (4) The immersed sample is rinsed and dried to obtain a zinc alloy implant having a calcium-zinc-phosphorus modified layer.

[0039] Specifically, in step (1), the zinc alloy substrate is polished with sandpaper to a size of 800-1200 mesh, preferably 1000 mesh.

[0040] Specifically, the concentration of H3PO4 is 7mL / L, the concentration of Ca(H2PO4)2·H2O is 7.92g / L, the concentration of Zn(H2PO4)2·2H2O is 1.55g / L, the concentration of NaNO3 is 2g / L, and the concentration of NaNO2 is 2g / L; H3PO4 is used to provide PO4 3- , Ca(H2PO4)2·H2O is used to provide Ca 2+ , Zn(H2PO4)2·2H2O is used to provide Zn 2+ ; NaNO3 and NaNO2 as promoters can speed up the reaction process, shorten the reaction time, and while promoting film formation, they can also improve the density and uniformity of the film layer and optimize the microstructure of the film layer.

[0041] Specifically, the pH value of the Ca-Zn-P bath in step (3) is adjusted to 4-6 using a 4-6 mol / L NaOH solution, the temperature of the Ca-Zn-P bath is 55-65°C, and the immersion time is 20-40 min; further, the pH value of the Ca-Zn-P bath is 5, the temperature is 60°C, and the immersion time is 30 min; the acidic Ca-Zn-P bath is Zn 2+ , Ca 2+ and PO4 3- Coexistence in solution provides an ideal environment.

[0042] Specifically, in step (4), the sample is dried at a temperature of 40-50° C. for 1-2 hours.

[0043] In another specific embodiment of the present invention, a zinc alloy implant having a calcium-zinc-phosphorus modified layer is provided for use as an implant material in the medical field.

[0044] Example 1

[0045] Disc-shaped (Φ10×3mm) zinc alloy (Zn-1.0Mg-0.5Ca) was selected as the substrate for material property testing, and Φ2×5mm was used as the in vivo femoral implant sample. The sample was polished to 1000 mesh with sandpaper. The prepared zinc alloy disk was immersed in a colloidal titanium phosphate solution for surface activation treatment to increase the nucleation site of the crystal. Subsequently, the prepared sample was placed in a Ca-Zn-P bath for the conversion process. The Ca-Zn-P bath was prepared with 7mL / L H3PO4, 7.92g / L Ca(H2PO4)2·H2O, 1.55g / L Zn(H2PO4)2·2H2O, 2g / L NaNO3, and 2g / L NaNO2. Before the immersion process, the pH of the Ca-Zn-P bath was adjusted to 5 using a 5 mol / L NaOH solution, and the temperature of the Ca-Zn-P bath was maintained at 60°C, and the zinc alloy substrate was placed in the Ca-Zn-P bath and immersed for 30 minutes. After the immersion treatment, the sample was taken out for rinsing, and the sample was dried at 40°C for 1 hour to prepare a zinc alloy implant with a calcium-zinc-phosphorus modified layer.

[0046] Comparative Example 1

[0047] A disc-shaped (Φ10×3mm) zinc alloy (Zn-1.0Mg-0.5Ca) was selected as the substrate for material performance testing, and a Φ2×5mm sample was used as the in vivo femoral implant sample. The sample was polished to 1000 mesh with sandpaper to obtain a zinc alloy implant.

[0048] Comparative Example 2

[0049] Disc-shaped (Φ10×3mm) zinc alloy (Zn-1.0Mg-0.5Ca) was selected as the substrate for material property testing, and Φ2×5mm was used as the in vivo femoral implant sample. The sample was polished to 1000 mesh with sandpaper. The prepared zinc alloy disk was immersed in a colloidal titanium phosphate solution for surface activation treatment to increase the nucleation site of the crystal. Subsequently, the prepared sample was placed in a Zn-P bath for the conversion process. The Zn-P bath was prepared with 30mL / L HNO3, 15mL / L H3PO4, 2g / L NaClO3, 5g / L Ca(NO3)2·4H2O, and 5g / L C6H8O7·H2O. Before the immersion process, the pH of the Zn-P bath was adjusted to 2.5 using a 5mol / L sodium hydroxide solution, and the temperature of the Zn-P bath was maintained at 25℃. The zinc alloy substrate was placed in the Zn-P bath and immersed for 30 minutes. After the immersion treatment, the sample was taken out for rinsing, and the sample was dried at 40°C for 1 h to prepare a zinc alloy implant with a Zn-P coating.

[0050] The zinc alloy implant with a calcium-zinc-phosphorus modified layer (Ca-Zn-P) prepared in Example 1 of the present invention, the zinc alloy implant (Zn) obtained in Comparative Example 1, and the zinc alloy implant with a zinc-phosphorus coating (Zn-P) obtained in Comparative Example 2 were subjected to the following experiments:

[0051] The surface morphology and chemical composition of the three zinc alloy coatings were characterized by field emission scanning electron microscopy equipped with energy dispersive spectroscopy (EDS), and X-ray diffraction using Cu-Kα radiation. A scanning speed of 10° per minute was performed between 5° and 90° with a step interval of 0.02° 2θ to examine the different phase compositions of the three samples. The topographic features and surface average roughness (Sa) of the three samples were measured about six times in different areas using confocal microscopy. The contact angles were collected by a wetting angle instrument using the sessile water droplet technique. A deionized water droplet (1 μL) was slowly dispensed onto the sample surface through a micro syringe at a relative humidity of 36-40%. In order to improve the reliability of the results, six points were detected on each sample surface and the calculated data were expressed as the mean value and standard deviation. In order to examine the Zn 2+ and Ca 2+ The release from bare Zn, Zn-P and Ca-Zn-P modified layers was determined by immersing the samples in sterile microcentrifuge tubes (15 mL) containing 10 mL of fresh phosphate buffered saline (PBS) solution at 37 °C under continuous shaking at 100 rpm for 1, 4, 7, 10 and 14 days. After reaching the preset time points, all the removed extracts were replaced with a new aliquot of culture medium. The released Zn was detected by ICP-OES. 2+ and Ca2+ The date shown represents the average of three sets of measurements. Figure 1-Figure 5 The experimental results.

[0052] in, Figure 1 The surface morphology of Zn, Zn-P, and Ca-Zn-P is shown. Figure 1 As shown, the exposed Zn alloy implant in Comparative Example 1 presents a flat surface with uniformly oriented scratches after the grinding process. In contrast, the coating with micro-nano structure obtained by chemical conversion completely covers the surface of the Zn alloy substrate. The Zn-P coating in Comparative Example 2 has a typical disc-shaped crystal morphology with sizes ranging from 1 to 4 microns. This difference in crystal size is due to the different orders of nucleation and growth. The crystals of about 2-4 microns initially formed overlap each other to form a compact bottom layer. The finer crystals of about 1-2 microns formed subsequently intersperse each other and are randomly embedded in the large crystals. Compared with the Zn-P coating, the Ca-Zn-P modified layer of Example 1 of the present invention presents irregular petal-shaped agglomerates formed by the accumulation of lamellar crystals. In addition, the lamellar crystals are closely arranged, while the irregular petal-shaped agglomerates are loosely distributed on the surface of the substrate. The enlarged micrographs show that the thickness of a single lamellar crystal is nanometer-sized (less than 10 nanometers), but the length is micrometer-sized (10-20μm). In addition, the edges of the plate-like crystals are herringbone shaped and arranged in parallel along the length direction. The significant changes in the crystal micromorphology of the Ca-Zn-P modified layer are mainly attributed to the unique growth mechanism of the Ca-Zn-P modified layer. The growth mechanism of the Ca-Zn-P modified layer is described by a typical radial nucleation mode, where the atoms forming the coating are deposited and nucleated in advance, and then the deposited atoms continue to aggregate and grow at the nucleation sites. Finally, the coating crystals grow continuously in a three-dimensional radial mode. In addition, due to the designed addition of Ca in the coating, 2+ , the crystals are significantly refined in the thickness direction, thus forming a lamellar micro-nanostructure. However, the growth process of the Zn-P coating is considered to be a nucleation and growth process. As the conversion time increases, the initial crystals expand into disk-like crystals. The microstructural features of the Ca-Zn-P modified layer can promote cell adhesion and osteogenesis, because the nanoscale lamellar crystals can induce the formation of osteogenesis and focal adhesion.

[0053] Figure 2The EDS results of Zn, Zn-P, and Ca-Zn-P are described. According to these results, the main elemental components of the zinc alloy implants are Zn and Mg. For the zinc alloy implants with coatings, oxygen (O), phosphorus (P), and zinc (Zn) elements were detected in the Zn-P coating, while an additional calcium (Ca) element was detected in the Ca-Zn-P modified layer of the present invention. In addition, the contents of O and P in the Zn-P coating and the Ca-Zn-P modified layer are comparable, while the Zn in the Zn-P coating is approximately the sum of the Zn and Ca in the Ca-Zn-P modified layer. This infers that the Ca 2+ To replace Zn 2+ The EDS results show that the coating is composed of phosphates with high Zn, P and O contents. In addition, Ca doping is successfully achieved in the Ca-Zn-P modified layer of the present invention, which may be due to the fact that Ca 2+ Participated in the formation process of the modified layer.

[0054] The response of cells around the implant is influenced by the synergistic effect of surface composition and micromorphology. The Zn-P coating is composed of smooth disc-like crystals without obvious sharp structures. 2+ The crystal morphology of the Ca-Zn-P modified layer changes to a lamellar structure, which is further arranged to form petal-like clusters. Since natural trabecular bone has a hierarchical structure at the micro-nano scale, the lamellar micro-nano crystal structure in the Ca-Zn-P modified layer shows better structural compatibility with bone tissue.

[0055] Figure 3 XRD patterns of Zn, Zn-P, and Ca-Zn-P are shown. All implants showed diffraction lines belonging to zinc, which were mainly detected at 43.231°, 36.296°, and 38.992° of 2θ. In addition, it is known that the Zn-Mg system exhibits a typical eutectic mixture type (Zn+Mg2Zn11). After the addition of Ca element to the Zn-Mg system, the CaZn13 phase can be dispersed in the Zn alloy. Since zinc oxide is easily formed on the surface of air, weak diffraction peaks of zinc oxide were found in the XRD spectrum. After the conversion treatment, the intensity of the diffraction peaks in the bare Zn alloy implants decreased or even disappeared, indicating that the surface coverage of the PCC coating increased. All the diffraction peaks are consistent with zinc phosphate (Zn3(PO4)2·4H2O) in the Zn-P coating. They were mainly detected at 9.690°, 19.416°, and 31.327° of 2θ. As the main phase component of the Ca-Zn-P modified layer, calcium zinc phosphate (CaZn2(PO4)2·2H2O) exhibits obvious peaks at 2θ angles of 10.3°, 19.3°, and 32.0°. The two conversion coatings exhibit strong and narrow diffraction peaks, indicating that the coatings have a high degree of crystallinity.

[0056] The deposition of the coating is determined by the supersaturation of the PCC solution, which enables the precipitation of phosphate crystals on the substrate. The Zn-P solution contains a sufficient concentration of Zn 2+ and PO4 3- , while Ca-Zn-P solution also requires Ca 2+ The acidity of the solution is Zn 2+ , Ca 2+ and PO4 3- The ideal environment for coexistence in solution without precipitation of any other products. Zinc alloys show high activity in phosphate solution, which induces the vigorous dissolution of the substrate and produces a large amount of Zn 2+ (Reactions (1) and (2)). The solubility of phosphate decreases as the pH of the solution near the substrate surface increases. Under the joint regulation of kinetic and thermodynamic factors, sufficient Zn 2+ With PO4 in solution 3- and / or Ca 2+ Combined to form insoluble phosphate crystals. Ultimately, mainly according to the reaction (reaction (3) and (4)), a disc-shaped zinc phosphate coating and a plate-shaped zinc calcium phosphate modified layer are precipitated on the substrate. As the number of crystals increases, the growth space is suppressed, resulting in a relatively close arrangement of the crystals. Ultimately, the prepared modified layer will be evenly and densely distributed on the zinc alloy implant.

[0057] Zn → Zn 2+ +2e - (1)

[0058] 2H + +2e - → H2↑ (2)

[0059] 3Zn 2+ + 2H2PO 4- + 2H + + 4H2O + 6e - → Zn3(PO4)2·4H2O(s) + 3H2↑ (3)

[0060] Ca 2+ + 2Zn 2+ + 2H2PO 4- + 2H2O → CaZn2(PO4)2·2H2O(s) + 4H + (4)

[0061] Figure 4 The three-dimensional morphological features of Zn, Zn-P, and Ca-Zn-P are shown. And the corresponding calculated surface average roughness (Sa). The results show that the surface roughness changes with the change of surface morphology ( Figure 1 ). Obviously, obvious grinding scratches are distributed on the bare zinc alloy implant, while the Zn-P coating and Ca-Zn-P modified layer show different surface roughness morphologies. The roughness calculation data showed that the bare zinc alloy implant had the smallest Sa value (0.15±0.02μm), which was attributed to the smooth surface state after grinding with sandpaper. In addition, the Sa values ​​of both the Zn-P coating (0.18±0.01μm) and the Ca-Zn-P modified layer (0.24±0.02μm) increased, which was because the substrate was covered with the coating. The increase in crystal size at the micro-nano scale may be a key factor affecting the roughness of the coating. The crystals of the Zn-P coating are disc-shaped and distributed on the zinc alloy substrate, without obvious sharpening structures ( Figure 1 ). However, the lamellar crystals in the Ca-Zn-P modified layer present a nanoscale structure in thickness but a microscale in length. In addition, the petal-like morphology formed by the stacking of lamellar structures can significantly roughen the surface state of the Zn alloy implant. The surface roughness will affect the biological behavior of cells, which acts as a guide for cell contact and forms a mechanical connection on the surface. In addition, the increase in the roughness of the coating will provide a suitable environment for the attachment of cells, which is conducive to achieving a strong bond with bone tissue.

[0062] Figure 4 The water drop morphology and calculated contact angles of Zn, Zn-P, and Ca-Zn-P are shown. Compared with the bare zinc alloy implant (104.9°±2.1°), the contact angle values ​​of the Zn-P coating and Ca-Zn-P modified layer decreased in turn, with values ​​of 35.3°±1.3° and 32.3°±0.4°. Combined with SEM morphology ( Figure 1 ), the significant reduction in contact angle is affected by the dense structure of the coating. In the Ca-Zn-P modified layer, the presence of gaps between the platelet crystals leads to a reduction in contact angle and improved wettability. During the chemical conversion process, higher hydrophilicity indicates a more favorable surface coverage. Since cell adhesion depends on the wettability of the surface, a hydrophilic surface is more suitable for cell adhesion.

[0063] Bare zinc alloy implants, zinc alloy implants with Zn-P coatings, and zinc alloy implants with calcium-zinc-phosphorus modified layers were immersed in phosphate buffered saline (PBS) solution for 1, 4, 7, 10, and 14 days. Figure 4 As shown, all samples showed Zn 2+ The release behavior of Ca 2+ It was only detected in the Ca-Zn-P group, which is consistent with the results of elemental composition ( Figure 2 ). In addition, Zn 2+ and Ca 2+A similar sustained release pattern was observed over a 14-day period. 2+ The cumulative release of Zn was higher than that of PCC-coated Zn implants, proving that PCC coating can control the Zn 2+ In addition, the Ca in the Ca-Zn-P modified layer 2+ The release amount is Zn 2+ This is in accordance with the atomic ratio of the phosphate calcium zincite coating. In addition, the appropriate amount of Ca released from the Ca-Zn-P modified layer 2+ It will effectively promote the repair of bone tissue. Due to the existence of nano-scale microstructures in the lamellar crystals and the relatively loose distribution of petal-like agglomerates, the ion release rate of the Ca-Zn-P modified layer is faster than that of the Zn-P coating.

[0064] To evaluate the osseointegration of PCC-coated zinc alloy implants in vivo, Figure 6 As shown in Figure 2, a cylindrical implant (Φ2×5 mm) was implanted into the defect of the femoral shaft. Eight weeks after surgery, Micro-CT and hard tissue sections were performed to evaluate the in vivo bone integration. Figure 7 As shown in the left figure, from the results of CT images and quantitative analysis, the new bone mass in the Ca-Zn-P group was higher than that in the other groups. The CT results did not show that the Zn-P group had better new bone mass, which may be due to the unfavorable microenvironment of bone formation in vivo. Figure 7 The results on the right show the bone formation near the implant, with more new bone bridges seen around the Ca-Zn-P modified layer. The newly formed bone was labeled with Calcein and Alizarin red at different time points. Figure 8 As shown, the Ca-Zn-P group showed a strong osteogenic advantage in both the early and late stages, indicating its ability to promote bone formation in vivo. Quantitative analysis results showed that there was more bone formation around Ca-Zn-P, verifying its better bone integration ability. The above results indicate that the Ca-Zn-P group promoted bone integration in the bone defect area. The Ca-Zn-P implant may regulate the immune microenvironment through its surface morphology and ion release in vivo, resulting in more new bone mass than other groups.

[0065] The embodiments described above provide a detailed description of the technical solutions of the present invention. It should be understood that the above are only specific embodiments of the present invention and are not intended to limit the present invention. Any modifications, supplements or similar substitutions made within the scope of the principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A method for preparing a zinc alloy implant having a calcium-zinc-phosphorus modified layer, It is characterized in that The zinc alloy implant with a calcium-zinc-phosphorus modified layer comprises a zinc alloy matrix and a Ca-Zn-P modified layer, wherein the Ca-Zn-P modified layer presents irregular petal-shaped masses formed by stacking of plate-like crystals and is loosely distributed on the surface of the zinc alloy matrix; the main phase composition of the calcium-zinc-phosphorus modified layer is CaZn 2 (PO 4 ) 2 ·2H 2 O; The thickness of a single plate-like crystal is less than 10 nm, the length is 10-20 μm, and the edge of the plate-like crystal is in a herringbone shape; The zinc alloy implant having a calcium-zinc-phosphorus modified layer reduces the cytotoxicity of the zinc alloy; The method for preparing the zinc alloy implant having a calcium-zinc-phosphorus modified layer comprises the following steps: (1) Grinding the zinc alloy substrate; (2) immersing the polished zinc alloy substrate into a colloidal titanium phosphate solution for surface activation treatment; (3) Immersing the surface-activated zinc alloy substrate in a Ca-Zn-P bath to perform a conversion process; the Ca-Zn-P bath is prepared by using H 3 PO 4 , with a concentration of 7.92 g / L Ca(H 2 PO 4 ) 2 ·H 2 O, Zn(H 2 PO 4 ) 2 ·2H 2 O, NaNO at a concentration of 2 g / L 3 , NaNO concentration of 2 g / L 2 Formulated; The pH value of the Ca-Zn-P bath in step (3) is adjusted to 5 using 4-6 mol / L NaOH, the temperature of the Ca-Zn-P bath is maintained at 60°C, and the immersion time is 30 min; (4) The immersed sample is rinsed and dried to obtain a zinc alloy implant having a calcium-zinc-phosphorus modified layer.

2. The method for preparing the zinc alloy implant having a calcium-zinc-phosphorus modified layer according to claim 1, It is characterized in that In step (1), the zinc alloy substrate is polished with sandpaper to a mesh size of 800-1200.

3. The method for preparing the zinc alloy implant having a calcium-zinc-phosphorus modified layer according to claim 1, It is characterized in that In step (4), the sample is dried at 40°C for 1 h.

Citation Information

Patent Citations

  • Method for preparing bioactive calcium-phosphorus coating on surface of degradable medical zinc alloy

    CN111218677A

  • Zinc alloy surface zinc phosphate chemical conversion coating as well as preparation method and application thereof

    CN113529062A